JCE: Difficult To Recommend This Fund At The Current Price
JCE: Difficult To Recommend This Fund At The Current Price
Source link
Similar Posts
How we created an advisor that survived the pandemic and Brexit
Most traders attempting to automate trading face the same problem: an advisor shows excellent results on historical data but drains the deposit on a real account. The reason often lies not in a coding error, but in a fundamental approach. Universal robots try to trade the same way around the clock, ignoring the fact that…
SOXL: How I Generate Good Income From Triple Leveraged ETF
This article was written by Follow Advanced education in economics, business management and engineering. Professional experience with product management and development in high tech industry, including advisory with multiple fintech startups. Have been investing in growth companies since 1998. Recent interest of investment also includes income-focused portfolio, fund-based approach. Analyst’s Disclosure: I/we have a beneficial…
Sakar Healthcare Shares Rally 4% on 9 Cancer Drug Approvals
November 7, 2025November 7, 2025 Shares of Sakar Healthcare Ltd rallied 4% on Friday, 7 November, after the company announced securing marketing approval for 9 drugs. In its regulatory filing, Sakar Healthcare announced securing 9 new marketing approvals for its oncology (cancer) drugs in Europe and emerging regions, increasing…
How Much You Really Need to Invest in a TFSA to Make $800 a Month
Did you know that your Tax-Free Savings Account (TFSA) can become a powerful monthly income machine? Many Canadians still consider the TFSA as a savings tool or a place for a few trades here and there. But used correctly, it can do much more than that. With the right monthly dividend stocks, your TFSA can…
